VasCog Virtual 2021

8th - 9th September, 2021




Lifestyle Factors

Vascular Risk Factors

Stroke Pathophysiology

Clinical Trials



Animal Models

Blood Brain Barrier



R Nick Bryan

Austin TX, USA

Martin Dichgans

Munich, Germany

Gary Rosenberg

Albuquerque, NM, USA

Sudha Seshadri

San Antonio, TX, USA

Joe Verghese

New York, USA

Joanna Wardlaw

Edinburgh, UK

Hilde van den Brink

Student representative

John T O’Brien

Professor of Old Age Psychiatry

Hugh Markus

professor of Neurology


11:45 - 12:45 - Oral Session I

Breakout Room 1: Biomarkers I -SVD Pathophysiology (Talks 5 min each)

Chairs: Chris Chen (Singapore), Perminder Sachdev (Australia) 

  1. Association of type 2 diabetes, according to the number of risk factors within target range, with structural brain abnormalities, cognitive performance and risk of dementia- April van Gennip (The Netherlands)
  2. Cerebrospinal fluid biomarkers, brain structural and cognitive performances between normotensive and hypertensive controlled, uncontrolled and untreated 70-year-old adults- Atef Badji (USA)
  3. Perivascular fibroblasts activity precedes the onset of ALS neurodegeneration with high plasma SPP1 associated with short patient survival- Sebastian Lewandowski (Sweden)
  4. AIDE dementia risk score relates to severity and progression of cerebral small vessel disease in healthy midlife adults: the prevent-dementia- Audrey Low (UK)
  5. The impact of Alzheimer biomarkers and vascular factors on cognitive decline in memory clinic patients- Veerle van Gils (The Netherlands)
  6. Validation of a novel clinical neurovascular coupling biomarker- Suzanne E. van Dijk (The Netherlands)
  7. Analyzing multimodal MRI at tract-level with neural networks enhances the prediction of cognitive performance in memory clinic patients with small vessel disease- Alberto De Luca (The Netherlands)
  8. Network-based lesion impact score is an independent predictor of post-stroke cognitive impairment- J. Matthijs Biesbroek (The Netherlands)
  9. Relationship between cerebrovascular pathology and resting-state functional connectivity: a systematic review- Natasha Clarke (Canada)

Breakout Room 2: Stroke, Cognition and Pathophysiology (Talks 5 min each)

Chairs: Ingmar Skoog (Sweden), Louise Allan (Exeter) 

  1. Trajectories of cognitive change following stroke: a stepwise decline towards dementia- Joao Delgado (UK)
  2. Long-Term Outcomes Among Nigerian Stroke Survivors - the CogFAST-Nigeria Study- Gabriel Ogunde (Nigeria)
  3. Brain regions involved in the strategic processes of verbal fluency: a mVLSM study in 337 stroke patients- Flore Dorchies (France)
  4. Patterns and predictors of short-term trajectory of post-stroke cognitive function- Jess Lo (Australia)
  5. Visuospatial dysfunction in Vascular Cognitive impairment subtypes- A comparative study from a tertiary care center in Kolkata- Ashwani Bhat (India)
  6. Pure vascular-ischemic disease and cognitive impairment - Elisabet Englund (Sweden)
  7. Association between Cerebral Small Vessel Disease and Alzheimer’s disease pathologies- Yuan Cai (China)
  8. Combined associations of cognitive and motor impairments with functional outcome in covert cerebral small vessel disease- Hanna Jokinen (Finland)
  9. Cerebral small vessel function in patients with CADASIL and sporadic cerebral small vessel disease: assessment of hemodynamic response function with 7T MRI– the Zoom@svds study, Hilde van den Brink (The Netherlands)

12:50 - 13:00 - Welcome/ Opening (10 min)

Convenors: Raj Kalaria, John O’Brien, Hugh Markus (UK)

13:00 - 13:30 - Plenary I

Clinical VCI: J Wardlaw (UK) 20 min with 10 min discussion

Chair: John O/Brien (UK)

13:30 - 14:45 - Symposium I

The importance of VRF and Heart Variability for Cognition and Dementia: 

Chairs: K Ikram and D Bos (The Netherlands)

  • Orthostatic hypotension/heart failure and dementia - Frank Wolters (The Netherlands) (12 min)
  • Heart rate variability/blood pressure variability and cognition/dementia -Yuan Ma (USA) (12 min)
  • Cardiac dysfunction and cognition/dementia - Saima Hilal (Singapore) (12 min)
  • Cardiac biomarkers: current state-of-the-art - Thomas Vanassche (Belgium) (12 min)

2 x ECR talks (open abstracts, 5 mins each)

  1. Visit-to-Visit Variability in Blood Pressure over 10 Years, Cognitive Decline and Incident Dementia in Three Community-Based Cohorts of Older Adults- Simin Mahinrad (USA)
  2. Investigating the risk of cardiovascular risk factor subgroups in cognitively normal elderly on Alzheimer’s disease: a latent class approach- Myuri Ruthirakuhan (Canada)


14:30 - 15:30 - E-poster Blitz session I

Chair:  Adrian Wong (Hong Kong)

  1. Prevalence of cognitive impairment and dementia in  a multi-ethnic elderly cohort the Singapore Epidemiology of Eye Diseases study (SEED)- Ting Pang (Singapore)
  2. Discriminant Validity of the Progressive Forgetfulness Question in a Stepwise Dementia Screening Approach in a Singaporean Elderly Population- Ting Pang (Singapore)
  3. Neurofilament light level correlates with brain atrophy and cognitive and motor performance in subjects with cerebral white matter hyperintensities- Marge Kartau (Finland)
  4. Age-associated changes in the renin-angiotensin system: implications for future clinical trials- Robert MacLachlan (UK)
  5. Renin-angiotensin system gene expression and dementia pathology in Alzheimer’s disease, vascular and mixed dementia- Hannah Tayler (UK)
  6. Angiotensinogen, ACE-1 and ACE-2 in Alzheimer’s disease and vascular dementia- Özge Güzel (UK)
  7. Fibrinogen activates microglia and drives extracellular vesicle mediated propagation of pro-inflammatory signaling- Austyn Roseborough (Canada)
  8. Relationships between Myeloperoxidase and the Cognitive and Neuroimaging Correlates of Mild Vascular Cognitive Impairment- Kritleen Bawa (Canada)
  9. Modelling Alzheimer’s Disease through Environmentally Induced Neurovascular Dysfunction within an In Vitro Cell Model- Ernesto Zarate-Aldrete (UK)
  10. Endothelin-1-mediated contraction of human brain pericytes is dysregulated in the presence of Aβ1-40- Elliott Hibbs (UK)
  11. Automatic quantification of perivascular spaces in T2-weighted images at 7T MRI- Hugo Kuijf (The Netherlands)
  12. Connection Between Kidney Function and Cognition in the Elderly- Tomas Månsson (Sweden)
  13. Low carotid end diastolic velocity is associated with white matter hyperintensities and cortical atrophy in the Swedish "Good Aging in Skane" study- Katarina Ellström (Sweden)
  14. Association of cerebral small vessel disease burden with brain structure and cognitive and vascular risk trajectories in mid-to-late life- Michelle G. Jansen (The Netherlands)
  15. Self-reported cognitive decline, emotional symptoms, and daytime sleep after ischemic stroke- Elisabeth Kliem (Norway)
  16. Social Cognition is Associated with General Cognitive Function Post-Stroke- Elise Gjestad (Norway)
  17. Prevalence of, and risk factors for, vascular cognitive impairment in CADASIL- Amy A Jolly (UK)

 15:30 - 16:00 - Break

16:00 - 17:00 - Symposium II 

Is Brain Inflammation relevant for VCI?

Chairs: Frank Eric de Leeuw (Netherlands) John O’Brien (UK)

  • PET studies of microglial activation and blood brain barrier dysfunction in SVD - Hugh Markus (UK) (15 min)
  • Reprogramming of the peripheral immune system in SVD - Niels Riksen (The Netherlands) (15 min)

2 x ECR talks (open abstracts, 5 mins each)

  1. A cluster of blood-based biomarkers reflecting extracellular matrix organization, inflammation and signal transduction relates to cerebral blood flow in patients with cardiovascular disease - L Malin Overmars (The Netherlands)
  2. Does 11C-PK11195 binding predict lesion growth at one year?- Daniel Tozer (UK)


17:00 - 17:30 - Plenary II

Brain vascular extracellular matrix and VCIG Rosenberg (USA) - 20 min with 10 min discussion

Chair:  Eric Smith (Canada)

17:30 - End of Day 1


08:20 - 08:30 - Welcome/ Opening (10 min)

08:30 - 09:00 - Plenary III

Genetics of Stroke and VCI-from discovery to clinical applications: M Dichgans (Germany)- 20 min 10 min discussion

Chair: Hugh Markus (UK)

09:00 - 10:00 - Symposium III

Cardiovascular risk management throughout the life course to prevent/treat dementia:

Chairs: M Muller & E Richard (The Netherlands)

  • Prevention of dementia: a life-course approach - Majon Muller (The Netherlands) (5min)
  • CVRM to prevent dementia - Edo Richard (The Netherlands) (15 min)
  • CVRM to treat dementia - Majon Muller (The Netherlands) (10 min)

2 x ECR on related topics (5 mins each)

  1. Pulsatility index outperforms conventional imaging markers in the association with cognition in community elderly - Withdrawn
  2. A systematic review into the relationship between blood pressure variability and grey and white matter structures - Daria Gutteridge (Australia)


10:00 - 10:10 - Viewpoint session

Aducanumab for Alzheimer's Disease: Anders Wallin (Sweden); Response: Vincent Mok (Hong Kong, China)

10:10 - 10:30 - Coffee Break

10:30 - 11:00 - Plenary IV

Risk Factors for SVD: an Asian Perspective: H-J Bae (S Korea)- 20 min 10 min discussion

Chair: SangYun Kim (S Korea)

11:00 - 12:00 - E-poster Blitz session II (3 min each)

Chair: Deborah Gustafson (USA)

  1. Association Between Blood Pressure Variability with Dementia and Cognitive Impairment: A Systematic Review and Meta-analysis- Philip Tully (Australia)
  2. The Relationship of Acute Delirium with Cognitive and Psychiatric symptoms: A longitudinal study- Vilde Nerdal (Norway)
  3. Neuropsychiatric symptoms accelerate cognitive impairment associated with small vessel disease- Anne Arola (Finland)
  4. Systemic endothelial function and cerebral microbleeds: a cross-sectional analysis within the Rhineland study- Gokhan Pehlivan (Germany)
  5. The brain renin-angiotensin system is altered in age and Alzheimer’s disease- Robert MacLachlan (UK)
  6. The relationship between cognitive reserve and change in cognition during the first three months post-stroke- Ragnhild Roaldsnes
  7. Metabolic syndrome is associated with poor cognition: a population-based study of 70-year-olds without dementia- Anna Marseglia (Sweden)
  8. Small and large MRI-visible perivascular spaces in the basal ganglia of Parkinson’s disease patients- Stephanie Berberian (Canada)
  9. Microstructural changes in the penumbras of cerebral small vessel disease lesions are associated with cognition and sleep- Joel Ramirez (Canada)
  10. Venous Collagenosis, White Matter Hyperintensity and the Perivascular Space - David Lahna (USA)
  11. Serum Placental Growth Factor as a Marker of Cerebrovascular Disease burden in patients with Alzheimer’s Disease- Liu-Yun Wu (USA)
  12. Higher total cholesterol in APOEe4 carriers contributes to Alzheimer’s disease risk: findings from the Alzheimer’s disease Neuroimaging Initiative- Michelle Dunk (USA)
  13. Does white matter hyperintensity location predict cognitive impairment in an elderly population?- Polly Roads (UK)
  14. Prevalence and correlates of white matter hyperintensities in Royal Canadian Air Force pilots and Aircrew- Joel Ramirez (Canada)
  15. Gait and Falls in Cerebral Amyloid Angiopathy- Breni Sharma (Canada)


12:05 - 12:35 - Plenary V

Gait as a biomarker for VCI: Joe Verghese (USA) - 20 min 10 min discussion

Chair: Suvarna Alladi (India)

12:35 - 13:00 - Lunch Break

 13:00 - 14:00 -Early Career Researchers (ECR) Session

"The future of VCI research: a collaborative approach"

Chairs: Hilde van den Brink (The Netherlands), Anna Marseglia (Sweden)

4 x ECR talks (open abstracts, 10 min each)

  1. Diffusion MRI harmonization enables joint-analysis of multicenter data of patients with cerebral small vessel disease – Bruno Miguel Brito Robalo (The Netherlands)
  2. Effects of vascular burden on cognition are mediated by atrophy, amyloid, and glucose metabolism: a multi-centre mixed cohort of small vessel disease and Alzheimer’s pathology- Julie Ottoy (USA)
  3. Risk factors for onset of post-stroke depression in diverse ethno-regional groups- Ben C.P. Lam (Australia)
  4. NOTCH3 variant position is associated with vascular NOTCH3 aggregation load in CADASIL patients- Gido Gravesteijn (The Netherlands)

14:00 - 14:30Plenary VI

Variation in global stroke burden and influence on clinical and brain VCI phenotypes: Implications for prevention: S Seshadri (USA) 20 min with 10 min discussion

Chair:  Sandra Black (Canada)

14:30 - 15:30 - Oral Session II

Breakout Room 1: Biomarkers I - White Matter Pathophysiology, Vascular Reactivity (Talks 5 min each)

Chairs: Geert Jan Biessels (The Netherlands), Eric Smith (Canada) 
  1. Strategic white matter hyperintensity locations for cognitive impairment in memory clinic patients: a large-scaled multicenter study- Mirthe Coenen (The Netherlands)
  2. Strategic white matter hyperintensity locations and cognitive functioning in community-dwelling individuals: rationale and design- Floor A.S. de Kort (The Netherlands)
  3. Sex differences in white matter hyperintensities are modified by menopause: the Rhineland study- Valerie Lohner (Germany)
  4. The association between cardiovascular risk factors and white matter hyperintensity MRI phenotypes- Jasmin A. Keller (The Netherlands)
  5. Cilostazol in Decreasing Progression of Cerebral White Matter Hyperintensities- Bonaventure Ip
  6. The relation between small vessel function and white matter integrity in patients with CADASIL: the zoom@svds study- Naomi Vlegels (The Netherlands)
  7. Vascular reactivity is decreased in early stages of dementia; a novel MRI biomarker- Suzanne E. van Dijk (The Netherlands)
  8. Cerebrovascular reactivity in cerebral amyloid angiopathy- Andrew E Beaudin (Canada)

Breakout Room 2: Blood Brain Barrier Pathophysiology, Models and Dementias Biomarkers I(Talks 5 min each)

Chairs: Marco Duering (Germany), Stuart Allan (UK) (Talks 5 min each)

  1. Uptake and replication of SARS-COV-2 in the cells of the neurovascular unit- Katherine Kellett (UK)
  2. Cognitive impairment post cardiac arrest - reperfusion and hypoperfusion damage- Elisabet Englund (Sweden)
  3. Phosphorylated-tau181 is a Predictor of Poststroke Cognitive Impairment: A Longitudinal Study- Li-Kai Huang,
  4. The relationship between late-life hypertension and disease pathology in Alzheimer’s, vascular, and mixed dementia- Hannah Tayler (UK)
  5. Blood-brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor protein-β in patients with subcortical small-vessel disease – a report from the Gothenburg Mild Cognitive Impairment study- Petronella Kettunen (Sweden)
  6. Loss of hippocampal pericytes in vascular dementia, post-stroke dementia and Alzheimer’s disease- Yoshiki Hase (UK)
  7. A cluster of blood-based biomarkers reflecting coagulation relates to the burden of cerebral small vessel disease- Sanne Kuipers (The Netherlands)
  8. Mitochondrial mechanisms and carbonic anhydrases mediate neurovascular dysfunction in CAA models- Silvia Fossati (USA)
  9. A dual potassium channelopathy underlies small vessel disease of the brain in a mouse model of Alzheimer’s disease- Harry Pritchard (UK)

15:30 - 15.40 - Concluding Comments  

VasCog Society Deborah Gustafson (USA); VasCog 2023 Ingmar Skoog (Sweden)

End of day 2 and VasCog 2021 Conference